Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals - Fiscal Year End 2017 Financial Results  (Replay)
    Wednesday, February 21, 2018 8:30 am EST
Toggle Summary Spring Bank Pharmaceuticals to Present at the East Coast IDEAS Investor Conference on May 18th in Boston
HOPKINTON, Mass. , May 01, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals (NASDAQ:SBPH) today announced that Martin Driscoll , president and chief executive officer of Spring Bank Pharmaceuticals , will present at the East Coast IDEAS Investor Conference on May 18, 2017 at the Boston Park
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial and Operational Results
Completes monotherapy dosing in first cohort of the ACHIEVE global Phase 2a clinical trial of SB 9200 in chronic HBV patients HOPKINTON, Mass. , April 28, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel
Toggle Summary Spring Bank Pharmaceuticals to Present Results from In Vivo Studies of SB 11285, a Novel STING agonist for Immuno-Oncology, at Keystone Symposia
HOPKINTON, Mass. , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. , (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced two abstracts on SB 11285 , its
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports 2016 Financial and Operational Results
HOPKINTON, Mass. , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today provided an update on recent corporate and
Toggle Summary Spring Bank Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference in NYC on February 16
Untitled Document HOPKINTON, MA / ACCESSWIRE / February 7, 2017 / Spring Bank Pharmaceuticals Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that Martin Driscoll,
Toggle Summary Spring Bank Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference in NYC
HOPKINTON, Mass. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases today announced that Martin Driscoll , President
Toggle Summary Garrett Winslow Joins Spring Bank as Vice President of Legal
HOPKINTON, Mass. , Jan. 04, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer and inflammatory diseases, today announced that Garrett Winslow, Esq.
Toggle Summary Spring Bank and Arbutus Biopharma Announce Preclinical Collaboration in Study of Chronic Hepatitis B
HOPKINTON, Mass. , Dec. 19, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, and Arbutus Biopharma Corporation (NASDAQ:ABUS)
Toggle Summary Spring Bank Pharmaceuticals Announces Financing of $15 Million
Proceeds to Supplement Development of SB 9200 and SB 11285 HOPKINTON, Mass. , Nov. 18, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2016 Financial Results
Reaffirms on track to report initial results from the first dosing cohort in ACHIEVE Phase 2 chronic Hepatitis B trial of SB9200 during the first half of 2017 HOPKINTON, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical